Palvella Therapeutics (PVLA) saw its stock price soar 5.58% during intraday trading on Wednesday, driven by positive analyst sentiment.
The surge follows pre-market announcements from two research firms raising their price targets for the company. Raymond James increased its target to $225 from $193, while Chardan lifted its target to $240 from $210, maintaining a Buy rating on the stock.
According to analyst polls, Palvella Therapeutics holds an average Buy rating with a mean price target of $229.44, indicating strong institutional optimism about the company's future performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.